Business
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – – Axatilimab abstracts highlight potential for long-term benefit in R/R chronic GVHD and tolerability of axatilimab with ruxolitinib in newly diagnosed chronic GVHD – NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that 23 abstracts, including six oral presentations, showcasing compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) data were accepted for presentation at the 67th American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida, December 6-9, 2025. “The breadth of the upcoming data presentations reflects the tremendous promise that Revuforj and Niktimvo hold across the treatment continuum for acute leukemia and chronic GVHD, respectively,” said Nick Botwood, MBBS, Head of Research & Development and Chief Medical Officer at Syndax. “In particular, we are excited to present new frontline datasets showcasing the tolerability of Revuforj in combination with standard of care therapies along with high rates of complete remission and MRD negativity, as well as the first real-world evidence for a menin inhibitor, and a retrospective review of usage in the post-transplant setting. We also look forward to the presentation of new data that highlight the potential for Niktimvo to provide long-term benefits in chronic GVHD and the feasibility of combining with ruxolitinib in newly diagnosed chronic GVHD.” The Company will host an in-person investor event, along with a live webcast, at the ASH Annual Meeting on Monday, December 8, 2025, at 7:00 a.m. ET to discuss key data presented at the meeting. The live webcast will be available on the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time. Key abstracts accepted for presentation at ASH 2025: Revumenib: An oral presentation will highlight results from a cohort of newly diagnosed patients in the Phase 2 SAVE trial of revumenib in combination with v...